AL INFORMATION
Item 1. Financial Statements
ODONATE THERAPEUTICS, INC.
Condensed Balance Sheets
(in thousands, except par value and share amounts)
| June 30, | December 31, |
| 2019 | 2018 |
| (Unaudited) |
| Assets |
| Current assets: |
| Cash | $ | 206,904 | $ | 139,050 |
| Prepaid expenses and other current assets | 2,916 | 750 |
| Total current assets | 209,820 | 139,800 |
| Property and equipment, net | 1,798 | 1,899 |
| Right-of-use lease assets | 1,913 | - |
| Restricted cash | 251 | 251 |
| Other | 810 | 723 |
| Total assets | $ | 214,592 | $ | 142,673 |
| Liabilities and Stockholders' Equity |
| Current liabilities: |
| Accounts payable | $ | 7,961 | $ | 10,777 |
| Accrued expenses | 13,360 | 7,365 |
| Lease liabilities, current portion | 502 | - |
| Deferred rent, current portion | - | 66 |
| Total current liabilities | 21,823 | 18,208 |
| Lease liabilities, less current portion | 1,908 | - |
| Deferred rent, less current portion | - | 461 |
| Total liabilities | 23,731 | 18,669 |
| Commitments and contingencies (Note 5) |
| Stockholders' equity: |
| Common stock, $0.01 par value—100,000,000 shares authorized; 31,474,990 and 26,747,438 shares issued and outstanding at June 30, 2019 and December 31, 2018, respectively | 292 | 244 |
| Additional paid-in capital | 376,168 | 252,012 |
| Accumulated deficit | (185,599 | ) | (128,252 | ) |
| Total stockholders' equity | 190,861 | 124,004 |
| Total liabilities and stockholders' equity | $ | 214,592 | $ | 142,673 |

See accompanying notes.
3
ODONATE THERAPEUTICS, INC.
Condensed Statements of Operations
(Unaudited)
(in thousands, except share and per share amounts)
| Three Months Ended | Six Months Ended |
| June 30, | June 30, |
| 2019 | 2018 | 2019 | 2018 |
| Operating expenses: |
| Research and development | $ | 26,453 | $ | 17,024 | $ | 53,084 | $ | 31,484 |
| General and administrative | 2,783 | 2,755 | 5,374 | 5,176 |
| Total operating expenses | 29,236 | 19,779 | 58,458 | 36,660 |
| Loss from operations | (29,236 | ) | (19,779 | ) | (58,458 | ) | (36,660 | ) |
| Interest income | 534 | 389 | 1,111 | 389 |
| Net loss | $ | (28,702 | ) | $ | (19,390 | ) | $ | (57,347 | ) | $ | (36,271 | ) |
| Net loss per share: |
| Basic and diluted | $ | (1.15 | ) | $ | (0.79 | ) | $ | (2.31 | ) | $ | (1.49 | ) |
| Weighted-average shares outstanding: |
| Basic and diluted | 24,893,232 | 24,402,466 | 24,788,404 | 24,376,885 |

See accompanying notes.
4
ODONATE THERAPEUTICS, INC.
Condensed Statements of Stockholders’ Equity
(Unaudited)
(in thousands, except share amounts)
| Common Stock | Additional Paid-in | Accumulated | Total Stockholders' |
| Shares | Amount | Capital | Deficit | Equity |
| Balance at December 31, 2018 | 26,747,438 | $ | 244 | $ | 252,012 | $ | (128,252 | ) | $ | 124,004 |
| Issuance of common stock under employee stock plans | 10,606 | - | 159 | - | 159 |
| Forfeiture of common stock underlying incentive units | (5,618 | ) | - | - | - | - |
| Equity-based compensation expense | - | - | 2,925 | - | 2,925 |
| Net loss | - | - | - | (28,645 | ) | (28,645 | ) |
| Balance at March 31, 2019 | 26,752,426 | $ | 244 | $ | 255,096 | $ | (156,897 | ) | $ | 98,443 |
| Issuance of common stock, net of issuance costs | 4,750,000 | 48 | 117,655 | - | 117,703 |
| Issuance of common stock under employee stock plans | 18,502 | - | 427 | - | 427 |
| Forfeiture of common stock underlying incentive units | (45,938 | ) | - | - | - | - |
| Equity-based compensation expense | - | - | 2,990 | - | 2,990 |
| Net loss | - | - | - | (28,702 | ) | (28,702 | ) |
| Balance at June 30, 2019 | 31,474,990 | $ | 292 | $ | 376,168 | $ | (185,599 | ) | $ | 190,861 |

| Common Stock | Additional Paid-in | Accumulated | Total Stockholders' |
| Shares | Amount | Capital | Deficit | Equity |
| Balance at December 31, 2017 | 26,890,356 | $ | 240 | $ | 235,034 | $ | (39,292 | ) | $ | 195,982 |
| Issuance of common stock, net of issuance costs | 441,073 | 4 | 9,844 | - | 9,848 |
| Forfeiture of common stock underlying incentive units | (445,740 | ) | - | - | - | - |
| Non-cash contributions for expenses | - | - | 64 | - | 64 |
| Equity-based compensation expense | - | - | 1,011 | - | 1,011 |
| Net loss | - | - | - | (16,881 | ) | (16,881 | ) |
| Balance at March 31, 2018 | 26,885,689 | $ | 244 | $ | 245,953 | $ | (56,173 | ) | $ | 190,024 |
| Issuance of common stock under employee stock plans | 5,019 | - | 99 | - | 99 |
| Equity-based compensation expense | - | - | 1,589 | - | 1,589 |
| Net loss | - | - | - | (19,390 | ) | (19,390 | ) |
| Balance at June 30, 2018 | 26,890,708 | $ | 244 | $ | 247,641 | $ | (75,563 | ) | $ | 172,322 |

See accompanying notes.
5
ODONATE THERAPEUTICS, INC.
Condensed Statements of Cash Flows
(Unaudited)
(in thousands)
| Six Months Ended |
| June 30, |
| 2019 | 2018 |
| Cash flows from operating activities: |
| Net loss | $ | (57,347 | ) | $ | (36,271 | ) |
| Adjustments to reconcile net loss to net cash used in operating activities: |
| Equity-based compensation expense | 5,915 | 2,600 |
| Depreciation and amortization | 180 | 60 |
| Non-cash contributions for expenses | - | 64 |
| Changes in operating assets and liabilities: |
| Prepaid expenses and other assets | (2,253 | ) | 1,399 |
| Accounts payable | (2,822 | ) | 287 |
| Accrued expenses | 5,995 | 2,343 |
| Deferred rent | - | 433 |
| Net cash used in operating activities | (50,332 | ) | (29,085 | ) |
| Cash flows from investing activities: |
| Purchases of property and equipment | (103 | ) | (1,289 | ) |
| Net cash used in investing activities | (103 | ) | (1,289 | ) |
| Cash flows from financing activities: |
| Proceeds from issuance of common stock, net of issuance costs | 117,703 | 9,848 |
| Proceeds from issuance of common stock under employee stock plans | 586 | 98 |
| Net cash provided by financing activities | 118,289 | 9,946 |
| Net increase (decrease) in cash and restricted cash | 67,854 | (20,428 | ) |
| Cash and restricted cash, beginning of period | 139,301 | 198,105 |
| Cash and restricted cash, end of period | $ | 207,155 | $ | 177,677 |
| Supplemental disclosure of cash flow information: |
| Initial recognition of right-of-use lease assets | $ | 2,215 | $ | - |
| Property and equipment purchases included in accounts payable | $ | 7 | $ | 113 |

See accompanying notes.
6
ODONATE THERAPEUTICS, INC.
Notes to Condensed Financial Statements
(Unaudited)
1. Business
Odonate Therapeutics, Inc. (“Odonate” or the “Company”) is a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. The Company’s initial focus is on the development of tesetaxel, an investigational, orally administered chemotherapy agent that belongs to a class of drugs known as taxanes, which are widely used in the treatment of cancer. Tesetaxel has several pharmacologic properties that make it unique among taxanes, including: oral administration with a low pill burden; a long (~8-day) terminal plasma half-life in humans, enabling the maintenance of adequate drug levels with relatively infrequent dosing; no history of hypersensitivity (allergic) reactions; and significant activity against chemotherapy-resistant tumors. In patients with metastatic breast cancer, tesetaxel was shown to have significant, single-agent antitumor activity in two multicenter, Phase 2 studies. The Company is currently conducting three studies in breast cancer, including a multinational, multicenter, randomized, Phase 3 study in patients with human epidermal growth factor receptor 2 (“HER2”) negative, hormone receptor (“HR”) positive metastatic breast cancer (“MBC”), known as CONTESSA. The Company’s goal for tesetaxel is to develop an effective chemotherapy choice for patients that provides quality-of-life advantages over current alternatives.
On June 28, 2019, the Company closed an underwritten public offering of 4,750,000 shares of common stock at a public offering price of $26.00 per share. The gross proceeds were $123.5 million, and the net proceeds were $117.7 million after deducting underwriting discounts and commissions and offering costs.
As of June 30, 2019, the Company had $206.9 million in cash. The Company has incurred operating losses and negative cash flows from operations since inception. Management believes the Company’s existing cash as of June 30, 2019 will be sufficient to meet the Company’s anticipated cash requirements through at least one year from the date this Quarterly Report on Form 10-Q is filed with the U.S. Securities and Exchange Commission (the “SEC”).
2. Basis of Presentation and Summary of Significant Accounting Policies
Basis of Presentation and Use of Estimates
The Company’s condensed financial statements contained in this Quarterly Report on Form 10-Q have been prepared in accordance with generally accepted accounting principles in the U.S. (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of SEC Regulation S-X. Accordingly, certain information and disclosures required by GAAP for annual financial statements have been omitted. In the opinion of management, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation have been included. Interim financial results are not necessarily indicative of results anticipated for the full year. These condensed financial statements should be read in conjunction with the Company’s audited financial statements and accompanying notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018.
The preparation of the Company’s condensed financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company’s condensed financial statements and accompanying notes. The most significant estimates and assumptions in the Company’s condensed financial statements relate to accrued expenses and equity-based compensation expense. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected.
7
Summary of Significant Accounting Policies
During the six months ended June 30, 2019, other than the policy described below and the removal of the deferred rent policy on the adoption of Accounting Standards Update (“ASU”) No. 2016-02, Leases (“ASU 2016-02”), there were no changes to the Company’s significant accounting policies as described in Note 2 to the audited financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018.
Leases
At lease commencement, the Company records a lease liability based on the present value of lease payments over the expected lease term. The Company calculates the present value of lease payments using the discount rate implicit in the lease, unless that rate cannot be readily determined. In that case, the Company uses its incremental borrowing rate, which is the rate of interest that the Company would have to pay to borrow on a collateralized basis an amount equal to the lease payments over the expected lease term. The Company records a corresponding right-of-use lease asset based on the lease liability, adjusted for any lease incentives received and any initial direct costs paid to the lessor prior to the lease commencement date.
After lease commencement, the Company measures its leases as follows: (i) the lease liability based on the present value of the remaining lease payments using the discount rate determined at lease commencement; and (ii) the right-of-use lease asset based on the remeasured lease liability, adjusted for any unamortized lease incentives received, any unamortized initial direct costs and the cumulative difference between rent expense and amounts paid under the lease agreement. Any lease incentives received and any initial direct costs are amortized on a straight-line basis over the expected lease term. Rent expense is recorded on a straight-line basis over the expected lease term.
Recent Accounting Pronouncements
In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2016-02. This guidance requires lessees to recognize operating leases with a term greater than one year on the balance sheet as a right-of-use asset and corresponding lease liability. ASU 2016-02 is effective for annual and interim reporting periods beginning after December 15, 2018. Although ASU 2016-02 is required to be adopted at the earliest period presented using a modified retrospective approach, the FASB issued ASU No. 2018-11, Leases (Topic 842): Targeted Improvements (“ASU 2018-11”), which allows for an alternative transition method of adoption by recognizing a cumulative-effect adjustment, if any, to the opening balance of retained earnings in the period of adoption.
The Company adopted ASU 2016-02 on January 1, 2019 utilizing the alternative transition method allowed for under ASU 2018-11. As a result, the Company recorded lease liabilities and right-of-use lease assets of $2.7 million and $2.2 million, respectively, on its balance sheet as of January 1, 2019. The lease liabilities represent the present value of the remaining lease payments of the Company’s San Diego Lease and New York Lease (see Note 5), discounted using the Company’s incremental borrowing rate as of January 1, 2019. The corresponding right-of-use lease assets are recorded based on the lease liabilities, adjusted for the unamortized lease incentives received and the cumulative difference between rent expense and amounts paid under the San Diego Lease and New York Lease. The adoption of ASU 2016-02 did not have a material impact on either the statement of operations or statement of cash flows for the three and six months ended June 30, 2019.
3. Net Loss per Share
Basic net loss per share is calculated by dividing net loss by the weighted-average shares outstanding during the period, without consideration of common stock equivalents. The basic net loss per share calculation excludes 1,896,695 and 2,485,662 outstanding shares of common stock held by Odonate Holdings, LLC (“Odonate Holdings”) as of June 30, 2019 and 2018, respectively, to be used to settle incentive units previously issued under the Odonate Management Holdings Equity Incentive Plan (the
8
“Management Plan”). These shares of common stock are subject to transfer to the Company and cancellation until such incentive units are vested and exercised and, as such, are considered common stock equivalents. Therefore, the shares of common stock held by Odonate Holdings are excluded from the basic net loss per share calculation until the incentive units are exercised.
Diluted net loss per share is calculated by adjusting weighted-average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period. Common stock equivalents, which consist of shares of common stock underlying incentive units and vested stock options, were excluded from the calculation of diluted net loss per share because they were anti-dilutive.
4. Balance Sheet Details
Property and equipment consisted of the following (in thousands):
| June 30, | December 31, |
| 2019 | 2018 |
| Leasehold improvements | $ | 1,113 | $ | 1,113 |
| Office equipment | 607 | 504 |
| Furniture and fixtures | 432 | 432 |
| Software | 130 | 126 |
| Total gross property and equipment | 2,282 | 2,175 |
| Less accumulated depreciation | (484 | ) | (276 | ) |
| Property and equipment, net | $ | 1,798 | $ | 1,899 |

Depreciation expense was $0.1 million and $0.2 million for the three and six months ended June 30, 2019, respectively, compared to $47,000 and $0.1 million, respectively, for the same periods in 2018.
Accrued expenses consisted of the following (in thousands):
| June 30, | December 31, |
| 2019 | 2018 |
| Accrued clinical development costs | $ | 10,082 | $ | 5,732 |
| Accrued compensation and related expenses | 3,009 | 1,619 |
| Other accrued expenses | 269 | 14 |
| Total accrued expenses | $ | 13,360 | $ | 7,365 |

5. Commitments and Contingencies
Lease Commitments
In March 2018, the Company entered into an agreement to lease office space in San Diego, California (the “San Diego Lease”) with aggregate payments of approximately $0.8 million over the term of the lease. The San Diego Lease expires on December 31, 2019. The San Diego Lease is classified as an operating lease.
In February 2018, the Company entered into an agreement to lease office space in New York, New York (the “New York Lease”) with aggregate payments of approximately $2.8 million over the 7-year term of the lease. The Company has an option to extend the New York Lease for an additional three years at the end of the initial term. Further, the Company provided a standby letter of credit of $0.3 million in lieu of a security deposit during the term of the lease, subject to a reduction 3.5 years after the lease commencement. As of June 30, 2019, $0.3 million was pledged as collateral for the letter of credit and recorded as restricted cash. The New York lease is classified as an operating lease.
9
Future minimum lease payments under the San Diego Lease and New York Lease as of June 30, 2019 are as follows (in thousands):
| 2019 | $ | 428 |
| 2020 | 376 |
| 2021 | 385 |
| 2022 | 399 |
| 2023 | 427 |
| Thereafter | 806 |
| Total future minimum lease payments | 2,821 |
| Less discount | (411 | ) |
| Total lease liabilities | $ | 2,410 |

The Company recorded lease liabilities and right-of-use lease assets for the San Diego Lease and New York Lease based on the present value of lease payments over the expected lease terms, discounted using the Company’s incremental borrowing rate. The option to extend the New York Lease was not recognized as part of the Company’s lease liability and right-of-use lease asset. Rent expense was $0.2 million and $0.4 million for the three and six months ended June 30, 2019, respectively, compared to $0.2 million and $0.3 million, respectively, for the same periods in 2018. Amortization of the right-of-use lease assets was $17,000 and $31,000 for the three and six months ended June 30, 2019, respectively.
Other Commitments
The Company enters into contracts in the normal course of business with contract research organizations, contract development and manufacturing organizations and other service providers and vendors. These contracts generally provide for termination on notice and, therefore, are cancellable contracts.
Contingencies
From time to time, the Company may become subject to claims and litigation arising in the ordinary course of business. The Company is not a party to any material legal proceedings, nor is it aware of any material pending or threatened litigation.
6. Stockholders’ Equity
Common Stock Sales
On June 28, 2019, the Company closed an underwritten public offering of 4,750,000 shares of common stock at a public offering price of $26.00 per share. The gross proceeds were $123.5 million, and the net proceeds were $117.7 million after deducting underwriting discounts and commissions and offering costs.
On December 11, 2017, the Company closed its initial public offering (the “IPO”) of 6,250,000 shares of common stock at a public offering price of $24.00 per share. On January 10, 2018, the underwriters exercised their option to purchase 441,073 additional shares of common stock in the IPO. The aggregate gross proceeds from the IPO were $160.6 million, and the net proceeds were $147.3 million after deducting underwriting discounts and commissions and offering costs.
Non-cash Contributions for Expenses
Non-cash contributions for expenses represent certain services and other benefits received by the Company from an affiliate without charge to the Company (see Note 10). These services and other benefits are recorded as expense with corresponding increases to additional paid-in capital. No expense
10
for services and other benefits provided without charge to the Company was recorded for the three and six months ended June 30, 2019 and the three months ended June 30, 2018. The Company recorded expense, and a corresponding increase to additional paid-in capital, of $0.1 million for the six months ended June 30, 2018 for services and other benefits provided without charge to the Company.
7. Equity Incentive Plans
2017 Stock Option Plan
A total of 4,800,000 shares of common stock have been reserved for issuance under the Odonate Therapeutics, Inc. 2017 Stock Option Plan (the “2017 Plan”). As of June 30, 2019, 1,467,981 shares of common stock remained available for future grants under the 2017 Plan.
2017 Employee Stock Purchase Plan
A total of 500,000 shares of common stock have been reserved for issuance under the Odonate Therapeutics, Inc. 2017 Employee Stock Purchase Plan (the “ESPP”). As of June 30, 2019, 462,640 shares of common stock remained available for future grants under the ESPP.
Management Plan
On December 6, 2017, the Company converted from a Delaware limited liability company to a Delaware corporation by filing a certificate of conversion with the Delaware Secretary of State, and changed its name from “Odonate Therapeutics, LLC” to “Odonate Therapeutics, Inc.” (the “Conversion”). Prior to the Conversion, the Company issued an aggregate of 2,931,402 incentive units under the Management Plan. As of June 30, 2019, 1,896,695 outstanding shares of common stock were held by Odonate Holdings to be used to settle incentive units previously issued under the Management Plan. Following the Conversion, the Company has not granted, and will no longer grant, any incentive units.
Equity Awards
The activity related to equity awards, which are comprised of stock options and incentive units, during the six months ended June 30, 2019 is summarized as follows:
| Equity Awards | Weighted-average Exercise Price per Share | Weighted-average Remaining Contractual Term(1) (years) | Aggregate Intrinsic Value(2) (millions) |
| Outstanding at December 31, 2018 | 5,361,920 | $ | 12.63 |
| Granted | 368,897 | $ | 20.00 |
| Exercised | (190,653 | ) | $ | 5.39 |
| Cancelled/forfeited | (324,822 | ) | $ | 19.01 |
| Outstanding at June 30, 2019 | 5,215,342 | $ | 13.02 | 9.3 | $ | 123.0 |
| Exercisable at June 30, 2019 | 1,347,938 | $ | 8.02 | 8.6 | $ | 38.7 |

(1) Represents the weighted-average remaining contractual term of stock options. The incentive units have no expiration.
(2) Aggregate intrinsic value represents the product of the number of equity awards outstanding or equity awards exercisable multiplied by the difference between the Company’s closing stock price per share on the last trading day of the period, which was $36.69 as of June 28, 2019, and the exercise price.
The total intrinsic value of equity awards exercised during the six months ended June 30, 2019 was $5.8 million. No equity awards were exercised during the six months ended June 30, 2018. The total fair value of equity awards vested during the six months ended June 30, 2019 and 2018 was $8.6 million and $1.2 million, respectively.
11
Equity-based Compensation Expense
For the six months ended June 30, 2019 and 2018, the weighted-average grant-date fair value per equity award was $13.32 and $15.81, respectively. The Company estimated the fair value of each equity award on the grant date using the Black-Scholes option-pricing model with the following assumptions:
| Six Months Ended |
| June 30, |
| 2019 | 2018 |
| Expected volatility | 74% – 75% | 72% – 73% |
| Expected life | 6 years | 6 years |
| Risk-free interest rate | 2.4% – 2.5% | 2.3% – 2.6% |
| Expected dividend yield | 0% | 0% |

Under the ESPP, eligible employees may purchase shares of the Company’s common stock twice per month at a price equal to 85% of the closing price of shares of the Company’s common stock on the date of each purchase. The benefit received by the employees, which is equal to a 15% discount on the shares of the Company’s common stock purchased, is recognized as equity-based compensation expense on the date of each purchase.
The classification of equity-based compensation expense is summarized as follows (in thousands):
| Three Months Ended | Six Months Ended |
| June 30, | June 30, |
| 2019 | 2018 | 2019 | 2018 |
| Equity-based compensation expense: |
| Research and development | $ | 2,573 | $ | 1,264 | $ | 5,073 | $ | 2,203 |
| General and administrative | 417 | 325 | 842 | 397 |
| Total equity-based compensation expense | $ | 2,990 | $ | 1,589 | $ | 5,915 | $ | 2,600 |

As of June 30, 2019, total unrecognized equity-based compensation expense related to unvested equity awards was $33.6 million, which will be recognized over a weighted-average period of 3.0 years. As of June 30, 2019, there was no unrecognized equity-based compensation expense related to shares of common stock issued under the ESPP.
8. Income Taxes
For the three and six months ended June 30, 2019 and 2018, the Company did not record a provision for income taxes due to having recorded a full valuation allowance against its deferred tax assets. As of June 30, 2019 and December 31, 2018, the Company established a full valuation allowance against its federal and state deferred tax assets due to the uncertainty surrounding the realization of such assets. As of June 30, 2019 and December 31, 2018, the Company had no unrecognized tax benefits. The Company does not anticipate there will be a significant change in unrecognized tax benefits within the next 12 months.
9. License Agreement
In 2013, the Company licensed rights to tesetaxel in all major markets from Daiichi Sankyo Company, Limited (“Daiichi Sankyo”), the original inventor of the product. Under the Daiichi Sankyo license agreement, the Company is obligated to use commercially reasonable efforts to develop and commercialize tesetaxel in the following countries: France, Germany, Italy, Spain, the United Kingdom and the U.S. The Company is required to make aggregate future milestone payments of up to $31.0 million, contingent on attainment of certain regulatory milestones. Additionally, the Company will pay Daiichi Sankyo a tiered royalty that ranges from the low to high single digits, depending on annual net sales of tesetaxel.
12
10. Related Party Transactions
Commencing in 2016, the Company received certain services and other benefits from an affiliate (the “Affiliate”) of the Chairman and Chief Executive Officer of the Company. The Company was not charged any fees for these services and other benefits, which included personnel costs for research and development and administrative functions, rent and facility costs and other direct expenses. No expense for services and other benefits provided without charge to the Company was recorded for the three and six months ended June 30, 2019 and the three months ended June 30, 2018. The Company recorded expense, and a corresponding increase to additional paid-in capital, of $0.1 million for the six months ended June 30, 2018 for services and other benefits provided without charge to the Company. Personnel costs were based on actual costs incurred by the Affiliate, which were allocated based on the estimated percentage of time employees spent working for Odonate on an employee-by-employee basis. Rent and facility costs were based on actual costs incurred by the Affiliate and allocated based on the Company’s use of shared space using headcount. Other direct expenses paid by the Affiliate were specifically identifiable to the Company and were allocated directly to the Company. The Chairman and Chief Executive Officer of the Company has elected to receive an annual salary of $1.00 and to not receive any bonuses, equity or other compensation.
Management believes that the method used to allocate costs is a fair and reasonable reflection of the utilization of the services provided to, or the benefit received by, the Company during the periods presented. The allocations may not, however, reflect the costs that the Company would have incurred if the Company had not received these services. Actual costs would depend on a number of factors, including strategic decisions in the areas of hiring, facility location and whether to outsource certain functions.
11. Subsequent Events
On July 2, 2019, the underwriters exercised in full their option in connection with the Company’s June 28, 2019 underwritten public offering to purchase 712,500 additional shares of common stock for gross proceeds of $18.5 million and net proceeds of $17.4 million after deducting underwriting discounts and commissions and offering costs.
13
f Financial Condition and Results of Operations
You should read the following discussion and analysis of our financial condition and results of operations together with our condensed financial statements and accompanying notes included in this Quarterly Report on Form 10-Q and our audited financial statements and accompanying notes included in our Annual Report on Form 10-K for the year ended December 31, 2018.
Forward-looking Statements
This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of the federal securities laws, and such statements may involve substantial risks and uncertainties. All statements, other than statements of historical facts included in this Quarterly Report on Form 10-Q, including statements concerning our plans, objectives, goals, strategies, future events, future revenues or performance, future expenses, financing needs, plans or intentions relating to acquisitions, business trends and other information referred to under this section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” are forward-looking statements. Forward-looking statements generally relate to future events or our future financial or operating performance. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “design,” “estimate,” “predict,” “potential,” “plan,” “anticipate,” “target,” “forecast” or the negative of these terms and similar expressions intended to identify forward-looking statements. Forward-looking statements are not historical facts and reflect our current views with respect to future events. Forward-looking statements are also based on assumptions and are subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements.
There are a number of risks, uncertainties and other important factors that could cause our actual results to differ materially from the forward-looking statements contained in this Quarterly Report on Form 10-Q. Such risks, uncertainties and other factors are described under “Risk Factors” in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2018. We caution you that these risks, uncertainties and other factors may not contain all of the risks, uncertainties and other factors that are important to you. In addition, we cannot assure you that we will realize the results, benefits or developments that we expect or anticipate or, even if substantially realized, that they will result in the consequences or affect us or our business in the way expected. All forward-looking statements in this Quarterly Report on Form 10-Q apply only as of the date made and are expressly qualified in their entirety by the cautionary statements included in this Quarterly Report on Form 10-Q. We undertake no obligation to publicly update or revise any forward-looking statements to reflect subsequent events or circumstances.
14
Company Overview
We are a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. Our initial focus is on the development of tesetaxel, an investigational, orally administered chemotherapy agent that belongs to a class of drugs known as taxanes, which are widely used in the treatment of cancer. Tesetaxel has several pharmacologic properties that make it unique among taxanes, including: oral administration with a low pill burden; a long (~8-day) terminal plasma half-life in humans, enabling the maintenance of adequate drug levels with relatively infrequent dosing; no history of hypersensitivity (allergic) reactions; and significant activity against chemotherapy-resistant tumors. In patients with metastatic breast cancer, tesetaxel was shown to have significant, single-agent antitumor activity in two multicenter, Phase 2 studies. We are currently conducting three studies in breast cancer, as shown in the following table, including a multinational, multicenter, randomized, Phase 3 study in patients with human epidermal growth factor receptor 2 (“HER2”) negative, hormone receptor (“HR”) positive metastatic breast cancer (“MBC”), known as CONTESSA. We expect to complete enrollment of CONTESSA in the second half of 2019 and report top-line results from CONTESSA in 2020. Our goal for tesetaxel is to develop an effective chemotherapy choice for patients that provides quality-of-life advantages over current alternatives.
Ongoing Tesetaxel Clinical Studies
| HER2= human epidermal growth factor receptor 2; HR=hormone receptor; MBC=metastatic breast cancer; TNBC=triple-negative breast cancer |

CONTESSA
CONTESSA is a multinational, multicenter, randomized, Phase 3 study of tesetaxel, an investigational, orally administered taxane, in patients with MBC. CONTESSA is comparing tesetaxel dosed orally at 27 mg/m2 on the first day of each 21-day cycle plus a reduced dose of capecitabine (1,650 mg/m2/day dosed orally for 14 days of each 21-day cycle) to the approved dose of capecitabine alone (2,500 mg/m2/day dosed orally for 14 days of each 21-day cycle) in approximately 600 patients randomized 1:1 with HER2 negative, HR positive MBC previously treated with a taxane in the neoadjuvant or adjuvant setting. Capecitabine is an oral chemotherapy agent that is considered a standard-of-care treatment in MBC. Where indicated, patients must have received endocrine therapy with or without a cyclin-dependent kinase (“CDK”) 4/6 inhibitor. Patients with central nervous system (“CNS”) metastases are eligible. The primary endpoint is progression-free survival (“PFS”) as assessed by an Independent Radiologic Review Committee (“IRC”). CONTESSA’s secondary efficacy endpoints are overall survival (“OS”), objective response rate (“ORR”) as assessed by the IRC and disease control rate (“DCR”) as assessed by the IRC.
15
In June 2019, the Independent Data Monitoring Committee (the “IDMC”) for CONTESSA recommended that the study continue with no modifications following a planned interim efficacy futility analysis. The interim efficacy futility analysis was based on a pre-specified analysis of the first approximate 100 PFS events that occurred in the study. The purpose of the interim efficacy futility analysis was to facilitate the early termination of the study if the IDMC determined that achieving a positive outcome on the primary endpoint would be futile.
CONTESSA 2
CONTESSA 2 is a multinational, multicenter, Phase 2 study of tesetaxel, an investigational, orally administered taxane, in patients with MBC. CONTESSA 2 is investigating tesetaxel dosed orally at 27 mg/m2 on the first day of each 21-day cycle plus a reduced dose of capecitabine (1,650 mg/m2/day dosed orally for 14 days of each 21-day cycle) in approximately 125 patients with HER2 negative, HR positive MBC not previously treated with a taxane. Capecitabine is an oral chemotherapy agent that is considered a standard-of-care treatment in MBC. Where indicated, patients must have received endocrine therapy with or without a CDK 4/6 inhibitor. Patients with CNS metastases are eligible. The primary endpoint is ORR as assessed by an IRC. The secondary efficacy endpoints are duration of response (“DoR”) as assessed by the IRC, PFS as assessed by the IRC, DCR as assessed by the IRC and OS.
CONTESSA TRIO
CONTESSA TRIO is a multi-cohort, multicenter, Phase 2 study of tesetaxel, an investigational, orally administered taxane, in patients with MBC.
| • | In Cohort 1, approximately 90 patients (with potential expansion to up to 150 patients) with locally advanced or metastatic triple-negative breast cancer (“TNBC”) who have not received prior chemotherapy for advanced disease will be randomized 1:1:1 to receive tesetaxel dosed orally at 27 mg/m2 on the first day of each 21-day cycle plus either: (1) nivolumab at 360 mg by intravenous infusion on the first day of each 21-day cycle; (2) pembrolizumab at 200 mg by intravenous infusion on the first day of each 21-day cycle; or (3) atezolizumab at 1,200 mg by intravenous infusion on the first day of each 21-day cycle. Nivolumab and pembrolizumab (PD-1 inhibitors) and atezolizumab (a PD-L1 inhibitor) are immuno-oncology (“IO”) agents approved for the treatment of multiple types of cancer. One of these agents, atezolizumab, in combination with the intravenously delivered taxane, nab-paclitaxel, was recently approved by the U.S. Food and Drug Administration (“FDA”) as a first-line treatment for patients with metastatic TNBC. Patients with CNS metastases are eligible. The dual primary endpoints for Cohort 1 are ORR and PFS. Secondary endpoints include DoR and OS. Efficacy results for each of the three PD-(L)1 inhibitor combinations will be assessed for correlation with the results of each of the three approved PD-L1 diagnostic assays. |

| • | In Cohort 2, approximately 40 elderly patients (with potential expansion to up to 60 patients) with HER2 negative MBC will receive tesetaxel monotherapy dosed orally at 27 mg/m2 on the first day of each 21-day cycle. Patients with CNS metastases are eligible. The primary endpoint for Cohort 2 is ORR. Secondary endpoints include PFS, DoR and OS. |

Components of Our Results of Operations
Research and Development Expense
Research and development expense consists primarily of costs associated with the development of our product candidates and includes: (i) salaries, benefits, travel, equity-based compensation expense and facility-related expense for personnel engaged in research and development functions; (ii) expense incurred under agreements with contract research organizations (“CROs”), investigative sites and consultants that conduct our nonclinical and clinical studies; (iii) manufacturing development and scale-up expense and the cost of acquiring and manufacturing clinical study materials and commercial materials, including manufacturing registration and validation batches; (iv) payments to consultants engaged in the development of our product candidates, including equity-based compensation expense, travel and other expense; and (v) costs related to compliance with quality and regulatory requirements.
16
Research and development expense is charged to operations as incurred when the expenditures relate to our research and development efforts and have no alternative future use. Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received.
All of our research and development expense incurred to date has been incurred in connection with the development of tesetaxel. We do not expect our research and development expense to increase significantly in the near term.
General and Administrative Expense
General and administrative expense consists primarily of salaries, benefits, travel, equity-based compensation expense and facility-related expense for personnel in finance and administrative functions. General and administrative expense also includes professional fees for legal, patent, consulting, accounting and audit services and other related costs. We do not expect our general and administrative expense to increase significantly in the near term.
Results of Operations
The following table summarizes our results of operations for each of the periods below (in thousands):
| Three Months Ended | Six Months Ended |
| June 30, | June 30, |
| 2019 | 2018 | 2019 | 2018 |
| Research and development expense | $ | 26,453 | $ | 17,024 | $ | 53,084 | $ | 31,484 |
| General and administrative expense | $ | 2,783 | $ | 2,755 | $ | 5,374 | $ | 5,176 |
| Interest income | $ | 534 | $ | 389 | $ | 1,111 | $ | 389 |

Research and Development Expense
The following table summarizes our research and development expense for each of the periods below (in thousands):
| Three Months Ended | Six Months Ended |
| June 30, | June 30, |
| 2019 | 2018 | 2019 | 2018 |
| Clinical development costs | $ | 16,571 | $ | 11,088 | $ | 32,919 | $ | 20,481 |
| Personnel and related costs | 6,843 | 4,587 | 13,982 | 8,653 |
| Equity-based compensation expense | 2,573 | 1,264 | 5,073 | 2,203 |
| Other research and development costs | 466 | 85 | 1,110 | 147 |
| Total research and development expense | $ | 26,453 | $ | 17,024 | $ | 53,084 | $ | 31,484 |

Research and development expense was $26.5 million and $53.1 million for the three and six months ended June 30, 2019, respectively, compared to $17.0 million and $31.5 million, respectively, for the same periods in 2018. The increase in research and development expense was due primarily to increased activities and headcount in connection with our tesetaxel clinical development program.
17
General and Administrative Expense
The following table summarizes our general and administrative expense for each of the periods below (in thousands):
| Three Months Ended | Six Months Ended |
| June 30, | June 30, |
| 2019 | 2018 | 2019 | 2018 |
| General and administrative costs | $ | 1,331 | $ | 1,768 | $ | 2,449 | $ | 2,945 |
| Personnel and related costs | 1,035 | 662 | 2,083 | 1,834 |
| Equity-based compensation expense | 417 | 325 | 842 | 397 |
| Total general and administrative expense | $ | 2,783 | $ | 2,755 | $ | 5,374 | $ | 5,176 |

General and administrative expense of $2.8 million and $5.4 million for the three and six months ended June 30, 2019, respectively, remained consistent compared to $2.8 million and $5.2 million, respectively, for the same periods in 2018.
Interest Income
Interest income was $0.5 million and $1.1 million for the three and six months ended June 30, 2019, respectively, compared to $0.4 million for both the three and six months ended June 30, 2018. Interest income consists of income generated from cash held in savings accounts.
Liquidity and Capital Resources
On June 28, 2019, we closed an underwritten public offering of 4,750,000 shares of common stock at a public offering price of $26.00 per share. The gross proceeds were $123.5 million, and the net proceeds were $117.7 million after deducting underwriting discounts and commissions and offering costs.
As of June 30, 2019 and December 31, 2018, we had cash in the amount of $206.9 million and $139.1 million, respectively. We believe that our existing cash as of June 30, 2019 will be sufficient to meet our anticipated cash requirements through at least one year from the date this Quarterly Report on Form 10-Q is filed with the U.S. Securities and Exchange Commission (the “SEC”).
We have incurred losses in each year since our inception. Our net loss was $28.7 million and $57.3 million for the three and six months ended June 30, 2019, respectively, compared to $19.4 million and $36.3 million, respectively, for the same periods in 2018. As of June 30, 2019 and December 31, 2018, we had an accumulated deficit of $185.6 million and $128.3 million, respectively. Substantially all of our operating losses resulted from expenses incurred in connection with advancing tesetaxel through development activities and general and administrative costs associated with our operations.
To date, we have funded our operations through the sale of equity securities. Since our inception, we have raised $374.1 million in net proceeds from the sale of equity securities.
The following table summarizes our net cash flow activity for each of the periods below (in thousands):
| Six Months Ended |
| June 30, |
| 2019 | 2018 |
| Net cash (used in) provided by: |
| Operating activities | $ | (50,332 | ) | $ | (29,085 | ) |
| Investing activities | (103 | ) | (1,289 | ) |
| Financing activities | 118,289 | 9,946 |
| Net increase (decrease) in cash and restricted cash | $ | 67,854 | $ | (20,428 | ) |

18
Net cash used in operating activities was $50.3 million and $29.1 million for the six months ended June 30, 2019 and 2018, respectively. Net cash used in operating activities was primarily the result of our net loss and change in working capital, partially offset by equity-based compensation expense and depreciation and amortization expense.
Net cash used in investing activities was $0.1 million and $1.3 million for the six months ended June 30, 2019 and 2018, respectively. Net cash used in investing activities was the result of purchases of property and equipment.
Net cash provided by financing activities was $118.3 million and $9.9 million for the six months ended June 30, 2019 and 2018, respectively. For the six months ended June 30, 2019, net cash provided by financing activities was primarily the result of net proceeds from the sale of common stock in an underwritten public offering. For the six months ended June 30, 2018, net cash provided by financing activities was the result of net proceeds from the exercise of the underwriters’ option to purchase additional shares of common stock in our initial public offering.
Until such time as we can generate substantial product revenues, we expect to finance our cash needs through equity offerings, debt financings, collaborations, strategic partnerships and/or licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be or could be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic partnerships or licensing arrangements with third parties, we may have to relinquish valuable rights to our product candidates, associated intellectual property, our other technologies, future revenue streams or research programs or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market our product candidate even if we would otherwise prefer to develop and market such product candidate ourselves.
Contractual Obligations and Commitments
In March 2018, we entered into an agreement to lease office space in San Diego, California (the “San Diego Lease”) with aggregate payments of approximately $0.8 million over the term of the lease. The San Diego Lease expires on December 31, 2019.
In February 2018, we entered into an agreement to lease office space in New York, New York (the “New York Lease”) with aggregate payments of approximately $2.8 million over the 7-year term of the lease. We have an option to extend the New York Lease for an additional three years at the end of the initial term. Further, we provided a standby letter of credit of $0.3 million in lieu of a security deposit during the term of the lease, subject to a reduction 3.5 years after the lease commencement. As of June 30, 2019, $0.3 million was pledged as collateral for the letter of credit and was recorded as restricted cash.
We enter into contracts in the normal course of business with CROs, contract development and manufacturing organizations and other service providers and vendors. These contracts generally provide for termination on notice and, therefore, are cancellable contracts.
In 2013, we licensed rights to tesetaxel in all major markets from Daiichi Sankyo Company, Limited (“Daiichi Sankyo”), the original inventor of the product. Under the Daiichi Sankyo license agreement, we are obligated to use commercially reasonable efforts to develop and commercialize tesetaxel in the following countries: France, Germany, Italy, Spain, the United Kingdom and the U.S. We are required to make aggregate future milestone payments of up to $31.0 million, contingent on attainment of certain
19
regulatory milestones. Additionally, we will pay Daiichi Sankyo a tiered royalty that ranges from the low to high single digits, depending on annual net sales of tesetaxel.
Off–Balance Sheet Arrangements
During the periods presented, we did not have, nor do we currently have, any off–balance sheet arrangements as defined under the rules of the SEC.
Jumpstart Our Business Startups Act
We are an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). Under this act, an emerging growth company can delay the adoption of new or revised accounting standards issued subsequent to the enactment of the JOBS Act until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. However, we intend to rely on other exemptions provided by the JOBS Act, including without limitation, not being required to comply with the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act of 2002, as amended. We will remain an emerging growth company until December 31, 2023 unless, prior to that time, we: (i) have more than $1.07 billion in annual gross revenue; (ii) have a market value for our common stock held by non-affiliates of more than $700 million as of the last day of our second quarter of any year; or (iii) issue more than $1.0 billion of non-convertible debt over a three-year period.
Critical Accounting Policies and Significant Judgments and Estimates
We believe the estimates, assumptions and judgments involved in the accounting policies described in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2018 are most critical to understanding and evaluating our reported financial results. During the six months ended June 30, 2019, there were no changes to our critical accounting policies and estimates as described in Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2018.
Recent Accounting Pronouncements
See Note 2 to our condensed financial statements included in Item 1 of this Quarterly Report on Form 10-Q.
We are a smaller reporting company, as defined by Rule 12b-2 under the Securities and Exchange Act of 1934 and in Item 10(f)(1) of Regulation S-K, and are not required to provide the information under this item.
Management’s Evaluation of our Disclosure Controls and Procedures
Our management, with the participation of our principal executive officer and our principal financial officer, evaluated, as of the end of the period covered by this Quarterly Report on Form 10-Q, the effectiveness of our disclosure controls and procedures. Based on that evaluation of our disclosure controls and procedures as of June 30, 2019, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures as of such date are effective at the reasonable assurance level. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the “Exchange Act”), means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a
20
company in the reports that it files or submits under the Exchange Act are recorded, processed, summarized and reported within the time periods specified in the U.S. Securities and Exchange Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.
Changes in Internal Control over Financial Reporting
There was no change in our internal control over financial reporting that occurred during our most recent quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
21
PART II. OTHER INFORMATION
We are not currently a party to any material legal proceedings.
Our business is subject to various risks, including those described in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2018. There have been no material changes from the risk factors disclosed in Item 1A of our Annual Report on Form 10-K, except that as of the closing of an underwritten public offering on June 28, 2019, we are no longer considered a “controlled company” within the meaning of Rule 5615(c)(1) of the Nasdaq Stock Market listing standards.
On December 11, 2017, we closed our initial public offering (“IPO”) of 6,250,000 shares of common stock at a public offering price of $24.00 per share. On January 10, 2018, the underwriters exercised their option to purchase 441,073 additional shares of common stock in our IPO. The aggregate gross proceeds from our IPO were $160.6 million, and the net proceeds were $147.3 million after deducting underwriting discounts and commissions and offering costs.
There has been no material change in the intended use of proceeds from our IPO as described in our final prospectus filed with the SEC pursuant to Rule 424(b)(4) on December 8, 2017.
None.
Not applicable.
None.
22
xhibits
| Exhibit No. | Description |
| 3.1 | Certificate of Incorporation of Odonate (incorporated herein by reference to Exhibit 3.1 to the Company’s Registration Statement on Form S-1 (File No. 333-221533), as filed with the SEC on November 27, 2017) |
| 3.2 | First Amended and Restated Bylaws, as adopted and effective as of June 20, 2019 (incorporated herein by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, as filed with the SEC on June 24, 2019) |
| 31.1 | Certification of the Principal Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934 |
| 31.2 | Certification of the Principal Financial Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934 |
| 32.1# | Certification of Principal Executive Officer and Principal Financial Officer pursuant to Rule 13a-14(b) or 15d-14(b) of the Exchange Act and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
| 101.INS | XBRL Instance Document |
| 101.SCH | XBRL Taxonomy Extension Schema Document |
| 101.CAL | XBRL Taxonomy Extension Calculation Linkbase Document |
| 101.DEF | XBRL Taxonomy Extension Definition Linkbase Document |
| 101.LAB | XBRL Taxonomy Extension Label Linkbase Document |
| 101.PRE | XBRL Taxonomy Extension Presentation Linkbase Document |

| # | Furnished herewith and not deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act. |

23
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| Odonate Therapeutics, Inc. |
| Date: July 24, 2019 | By: | /s/ Kevin Tang |
| Kevin Tang |
| Chairman and Chief Executive Officer |
| (principal executive officer) |
| /s/ Michael Hearne |
| Michael Hearne |
| Chief Financial Officer |
| (principal financial and accounting officer) |

24

Question: What is the percentage of the underwriting discounts and commissions in relation to the aggregate gross proceeds from the company's initial public offering (IPO)?

Solution:
def solution():
     #Define variables name and value

    aggregate_gross_proceeds = 160.6 # in millions
    net_proceeds = 147.3 # in millions

    #Do math calculation to get the answer
    underwriting_costs = aggregate_gross_proceeds - net_proceeds # in millions
    percentage = (underwriting_costs / aggregate_gross_proceeds) * 100

    answer = round(percentage, 2) # rounding the result to two decimal places
    return answer


Answer: 8.28